# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.72) by 2...
HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.
Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second...
HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.
Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.